Linda Yaccarino Named CEO of Emed Health Tech Platform

Linda Yaccarino Joins eMed Population Health as CEO

Following her departure from X, Linda Yaccarino will assume the position of chief executive officer at eMed Population Health. This AI-driven startup is developing a technology platform specifically for patients utilizing GLP-1 medications.

Transition from X

Prior to this appointment, Yaccarino held a prominent position as an advertising executive at NBCUniversal for many years. She then transitioned to X, serving as CEO for a two-year period.

During her time at X, Yaccarino successfully influenced the platform’s advertising revenue model, achieving positive results despite a shared strategy with Elon Musk that prioritized limited content moderation.

Why eMed Selected Yaccarino

Although Yaccarino’s background isn't in health technology, eMed highlighted her “exceptional ability to forge new partnerships” as a key reason for her selection. Her recent role at X also significantly raised her profile within the technology sector, increasing visibility for the startup.

eMed’s Platform Evolution

Initially, eMed developed a platform to support at-home COVID-19 rapid antigen tests, providing users with guidance on proper test administration.

The company’s focus has now shifted to GLP-1s, a category of drugs including Ozempic, used for both weight management and the treatment of type 2 diabetes.

Yaccarino’s Vision for eMed

“In the current healthcare landscape, leadership demands a bold and unwavering spirit – one that not only fosters growth but also dares to reimagine the industry,” Yaccarino stated in a press release.

“We are strategically positioned to embody this leadership, dedicated to enhancing global healthcare through our innovative services and platforms.”

eMed Population Health aims to improve healthcare outcomes through its AI-powered platform.